Twist Bioscience shares reach a new 52-week peak following selection by Anthropic for a protein design evaluation.

TWST · Twist Bioscience Corporation

The AI's read

Anthropic picked Twist to independently produce and test AI-designed proteins, giving Twist a visible role in AI-driven biologics validation. That matters because independent wet-lab validation is a choke point for AI drug discovery credibility. The market already responded aggressively: TWST jumped ~18% to a 52-week high and RSI sits near 73. Price is well above short- and mid-term averages and momentum looks stretched. We lean neutral. The deal is bullish for credibility, but the headline move and limited near-term revenue evidence cut the asymmetric upside, so watch for follow-through or a pullback.